Skip to main content

Table 1 Comparison between the group without and with TMP-SMX as PJP prophylaxis

From: The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study

  Total No TMP-SMX TMP-SMX P value
  N = 343 (100 %) N = 131 (38.2 %) N = 212 (61.8 %)  
Variables     
 Age recipient 52 (40–61) 52 (40–59) 52 (39–61) 0.420
 BMI recipient 25.2 +/−4.5 24.7 +/− 4.2 25.5 +/−4.6 0.128
 Female gender 152 (44.3) 65 (49.6) 87 (41.0) 0.120
 Diabetes Mellitus (a) 94 (27.4) 25 (19.1) 69 (32.5) 0.007
 Age donor 50 (40–57) 49 (39–57) 51 (41–57) 0.232
 Allograft from deceased donor 215 (62.7) 83 (63.4) 132 (62.3) 0.839
 Delayed graft function 109 (31.8) 42 (32.1) 67 (31.6) 0.930
 Acute rejection 80 (23.3) 31 (23.7) 49 (23.1) 0.925
 Indwelling urological catheter (b) 53 (15.5) 10 (7.6) 43 (20.3) 0.002
 First transplantation 294 (85.7) 113 (86.3) 181 (85.4) 0.821
 CMV disease 26 (7.6) 13 (9.9) 13 (6.1) 0.197
Maintenance therapy     <0.001
 Tacrolimus-MMF-steroids 205 (59.8) 49 (37.4) 156 (73.2)  
 MMF-cyclosporine-steroids 38 (11.1) 28 (21.4) 10 (4.7)  
 MA-cyclosporine-steroids 100 (29.2) 54 (41.2) 46 (21.7)  
Induction therapy     
 Basiliximab 216 (63.0) 82 (62.6) 134 (63.2) 0.909
Primary renal disease     
 Hypertension 88 (25.7) 23 (17.6) 65 (30.7)  
 Cystic renal disease 49 (14.3) 18 (13.7) 31 (14.6)  
 IgA nephropathy 28 (8.2) 15 (11.5) 13 (6.1)  
 Diabetes 20 (5.8) 7 (5.3) 13 (6.1)  
 Focal segmental glomerulosclerosis 27 (7.9) 11 (8.4) 16 (7.5)  
 Reflux and anatomical abnormalities 25 (7.3) 11 (8.4) 14 (6.6)  
 Glomerulonephritis 26 (7.6) 10 (7.6) 16 (7.5)  
 Unknown origin 27 (7.9) 12 (9.2) 15 (7.1)  
 Others 53 (15.5) 24 (18.3) 29 (13.7)  
Bacteriuria outcomes:     
 No bacteriuria 211 (61.5) 94 (71.7) 117 (55.2) 0.002
 Bacteriuria 132 (38.5) 37 (28.2) 95 (44.8)  
Subtype of bacteriuria     
- only ASB 63 (18.4) 17 (13.0) 46 (21.7)  
- cystitis 26 (7.6) 5 (3.8) 21 (9.9)  
- AGPN 43 (12.5) 15 (11.5) 28 (13.2)  
  1. Continuous variables are depicted as mean with +/− standard deviation or as median with (25–75 %) interquartile range. Nominal variables are depicted as the total number analysed with its percentage (%). AGPN allograft pyelonephritis, ASB asymptomatic bacteriuria, CI confidence interval, CMV cytomegalovirus, MA mycophenolic acid, MMF mycophenolate mofetil, TMP-SMX trimethoprim-sulfamethoxazole
  2. a: The variable “diabetes mellitus” includes type 1, type 2 diabetes and new onset of diabetes after transplantation (NODAT), irrespective of whether it was the primary disease which led to renal failure. b: The variable “Indwelling urological catheter” represents Foley catheter, nephrostomy catheter and intermittent self-catheterisation